Novel Antifungal Agents with Dual Mechanism of Action
With a clear and growing unmet need, a novel mechanism of action, and demonstrated in vitro superiority over current standard-of-care agents, these novel boron-based antifungal agents represent a compelling early-stage opportunity with significant commercial and public health relevance.
Background:
Invasive fungal infections caused by opportunistic...
Published: 7/24/2026
|
Inventor(s): Bhaskar Das, Joshua Nosanchuk, Daniel Miranda
Keywords(s): Chemistry, Featured, Healthcare, Pharmaceutical, Research Tool, Screening, Technologies, Therapeutic and Vaccines
Category(s): Campus > University at Buffalo, Technology Classifications > Drug Design and Synthesis, Technology Classifications > Therapeutics and Vaccines
|
Novel Small Molecule Anabolic Agents for Osteoporosis
-Analogs of a naturally occurring phytoestrogen that hold promise for the treatment of osteoporosis and other conditions impacting peri- and post-menopausal women.
Background:
Menopause significantly speeds bone loss and increases the risk of osteoporosis, a condition characterized by decreased bone mineral density and which impacts more than 200M...
Published: 7/24/2026
|
Inventor(s): Bhaskar Das, Hiranmoy Das
Keywords(s): Featured, Pharmaceutical, Research Tool, Technologies
Category(s): Campus > University at Buffalo, Technology Classifications > Drug Design and Synthesis, Technology Classifications > Therapeutics and Vaccines
|
Novel Small Molecule Agents for Glioblastoma
Brain-penetrant small molecule agents possessing a dual targeting mechanism of action (LonP1 and CT-L proteasome inhibition) that may overcome resistance mechanisms that currently plague standard of care treatments for brain tumors such as glioblastoma.
Background:
Malignant astrocytomas, including glioblastoma (GBM), represent highly aggressive intracranial...
Published: 7/10/2026
|
Inventor(s): Bhaskar Das, Daniela Bota
Keywords(s): Chemistry, Nanotechnology, Pharmaceutical, Research Tool, Screening, Technologies, Therapeutic and Vaccines
Category(s): Campus > University at Buffalo, Technology Classifications > Drug Design and Synthesis, Technology Classifications > Therapeutics and Vaccines
|
Apelin-Receptor (APJ) Antagonists
A series of stable, small molecule compounds that inhibit an alternative (non-VEGF) angiogenic pathway that is overexpressed in a variety of cancers.
Background:
Antiangiogenic drugs targeting the vascular endothelial growth factor (VEGF) signaling pathway are widely used to treat solid tumors and ocular conditions such as wet AMD. However, anti-VEGF...
Published: 6/19/2026
|
Inventor(s): Youngjae You, Sukyung Woo, Ganesh Bist, Ahmed Osama Mahmoud Abdel Elsheikh
Keywords(s): Technologies
Category(s): Campus > University at Buffalo, Technology Classifications > Therapeutics and Vaccines, Technology Classifications > Drug Design and Synthesis
|